Interviews

Explore how allostatic load, using routine labs and vitals, may strengthen early-onset cancer risk prediction and guide earlier prevention in community oncology.

Joseph Mikhael, MD, MEd, describes the impact of the FDA's approval of subcutaneous isatuximab with an on-body injector device.

MD Anderson trials test psilocybin therapy for head and neck cancer patients and survivors, aiming to curb suicide risk and ease treatment trauma.

KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable toxicity and longer responses.

KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses and guide future menin-based regimens.

Edgardo Santos, MD, discusses ROS1+ NSCLC treatment advances, taletrectinib data, toxicity profiles, and emerging therapies from recent Case-Based Roundtables.

New research shows T-cell receptor sequencing can reveal immune signatures of precancer and cancer in Lynch syndrome carriers, aiding early detection.

Doris K. Hansen, MD, discusses what she hopes long-term real-world data on CAR T-cell therapy will show in order to better inform treatment of multiple myeloma.

A 940-patient real-world study confirms alectinib outperforms crizotinib in ALK-positive NSCLC, mirroring results from the landmark ALEX trial.

Heather J. Landau, MD, discusses the most exciting outcomes observed in a trial of BCMA-targeted NXC-201 for light chain amyloidosis.

Doris K. Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

During a live event, Prerna Mewawalla, MD, discussed the choice between bispecific antibody therapy and CAR T-cell therapy in myeloma as both therapies have been introduced earlier in sequence.

Lung cancer increasingly hits never-smoking women; learn how biomarker testing, earlier screening, and stronger self-advocacy speed diagnosis and unlock better treatments.

Two new oncologists share raw truths on fellowship loneliness, fear of autonomy, and building networks that make the leap to faculty survivable.

Oral golcadomide with rituximab delivers high responses and manageable safety, enabling outpatient care for relapsed follicular lymphoma.

Golcadomide plus rituximab shows deep, durable responses in relapsed follicular lymphoma, with manageable neutropenia and limited added toxicity.

In an interview, Melody Chang, MBA, RPh, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.

Adam Cuker, MD, MS, discusses how the goals of treatment for immune thrombocytopenia have developed beyond managing platelet count.

Peter Voorhees, MD, discusses the cost-benefit question of adding pomalidomide to daratumumab and talquetamab in early relapsed multiple myeloma.

In an interview, Peter Voorhees, MD, discusses why talquetamab is typically sequenced after BCMA-targeting agents and the unique situations where it might be used first.

Virtual behavioral health embedded in community oncology boosts access for Black patients and patients on Medicaid, easing distress and improving quality of life.

Genome sequencing speeds tumor mutation discovery, boosting targeted cancer therapies and cell/gene treatments while raising urgent questions about data ownership, reporting uncertainty, and ethics.

Data link food deserts to metastatic breast cancer mutations and shorter survival, urging oncologists to screen for food insecurity.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

INSIGHT tests if NSCLC super-responders with pathologic complete response can skip adjuvant durvalumab, reducing toxicity without sacrificing survival.

Heather J. Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL amyloidosis.

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims to shift induction therapy standards worldwide.

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML therapy and maintenance.